{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:28:03Z","timestamp":1793755683080,"version":"4.6.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"DOI":"10.1007\/s10120-026-01795-y","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:40:35Z","timestamp":1787722835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognosis-predicting factor of gastrectomy after systemic cancer therapy for cStage IVB gastric cancer"],"prefix":"10.1007","author":[{"given":"Takumi","family":"Habu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7365-8733","authenticated-orcid":false,"given":"Takahiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Terajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izuma","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsumasa","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kuwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"3","key":"1795_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1795_CR2","volume-title":"TNM classification of malignant tumours","author":"LH Sobin","year":"2017","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. United Kingdom: Wiley-Blackwell; 2017."},{"key":"1795_CR3","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer A. Japanese Gastric Cancer Treatment guidelines 2021 (6th edition). Gastric Cancer. 2023;26(1):1\u201325.","DOI":"10.1007\/s10120-022-01331-8"},{"issue":"2","key":"1795_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2. 2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167\u201392.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"1795_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10120-015-0575-z","volume":"19","author":"K Yoshida","year":"2016","unstructured":"Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19(2):329\u201338.","journal-title":"Gastric Cancer"},{"issue":"3","key":"1795_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/jjco\/hyae174","volume":"55","author":"R Kita","year":"2025","unstructured":"Kita R, Yasufuku I, Takahashi N, Mizusawa J, Sano Y, Fukuda H, et al. Randomized controlled phase III study comparing chemotherapy alone versus conversion surgery after a remarkable response to chemotherapy in patients with initially unresectable cStage IVB or pStage IV gastric cancer (JCOG2301, Conversion study). Jpn J Clin Oncol. 2025;55(3):304\u201310.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"1795_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1186\/s12885-017-3918-9","volume":"17","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone versus chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction\u2014a phase III trial of the German AIO\/CAO-V\/CAOGI. BMC Cancer. 2017;17(1):893.","journal-title":"BMC Cancer"},{"issue":"9","key":"1795_CR8","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","volume":"3","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, et al. Effect of Neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction Cancer: the AIO-FLOT3 trial. JAMA Oncol. 2017;3(9):1237\u201344.","journal-title":"JAMA Oncol"},{"key":"1795_CR9","doi-asserted-by":"publisher","first-page":"114062","DOI":"10.1016\/j.ejca.2024.114062","volume":"204","author":"TE Kroese","year":"2024","unstructured":"Kroese TE, Bronzwaer S, van Rossum PSN, Schoppman SF, Deseyne P, van Cutsem E, et al. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). Eur J Cancer. 2024;204:114062.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1795_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/ags3.12733","volume":"8","author":"K Hara","year":"2024","unstructured":"Hara K, Cho H, Onodera A, Endo K, Maezawa Y, Aoyama T, et al. Long-term treatment outcomes in gastric cancer with oligometastasis. Ann Gastroenterol Surg. 2024;8(1):60\u201370.","journal-title":"Ann Gastroenterol Surg"},{"issue":"2","key":"1795_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10120-017-0738-1","volume":"21","author":"K Yamaguchi","year":"2018","unstructured":"Yamaguchi K, Yoshida K, Tanahashi T, Takahashi T, Matsuhashi N, Tanaka Y, et al. The long-term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer. 2018;21(2):315\u201323.","journal-title":"Gastric Cancer"},{"issue":"2","key":"1795_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ags3.12515","volume":"6","author":"K Yoshida","year":"2022","unstructured":"Yoshida K, Yasufuku I, Terashima M, Young Rha S, Moon Bae J, Li G, et al. International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg. 2022;6(2):227\u201340.","journal-title":"Ann Gastroenterol Surg"},{"key":"1795_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010086","author":"HJ Choe","year":"2019","unstructured":"Choe HJ, Kim JW, Han SH, Lee JH, Ahn SH, Park DJ, et al. Conversion surgery in metastatic gastric cancer and cancer dormancy as a prognostic biomarker. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers12010086.","journal-title":"Cancers (Basel)"},{"issue":"9742","key":"1795_CR14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"issue":"10294","key":"1795_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"issue":"2","key":"1795_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347.","journal-title":"Lancet Oncol"},{"issue":"7903","key":"1795_CR17","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","volume":"603","author":"K Shitara","year":"2022","unstructured":"Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942\u20138.","journal-title":"Nature"},{"issue":"11","key":"1795_CR18","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Yanez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1795_CR19","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341.","journal-title":"Nat Med"},{"issue":"10389","key":"1795_CR20","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655\u201368.","journal-title":"Lancet"},{"key":"1795_CR21","doi-asserted-by":"publisher","first-page":"100086","DOI":"10.1016\/j.esmogo.2024.100086","volume":"5","author":"U Okazaki","year":"2024","unstructured":"Okazaki U, Nakayama I, Sakamoto N, Kuwata T, Kawazoe A, Yoshida M, et al. Clinical implementation of simultaneous multiple biomarkers testing for metastatic or recurrent gastroesophageal adenocarcinoma: a single-institutional experience. ESMO Gastrointest Oncol. 2024;5:100086.","journal-title":"ESMO Gastrointest Oncol"},{"issue":"2","key":"1795_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1795_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313.","journal-title":"Ann Surg"},{"key":"1795_CR24","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer A. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101\u201312.","DOI":"10.1007\/s10120-011-0041-5"},{"issue":"3","key":"1795_CR25","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"1795_CR26","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212\u201324.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1795_CR27","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1245\/s10434-025-18641-7","volume":"33","author":"T Habu","year":"2026","unstructured":"Habu T, Ushiyama S, Nakayama I, Yura M, Yoshida M, Sakamoto N, et al. Is surgery necessary for stage IVB gastric cancer showing clinical complete response to chemotherapy or systemic cancer therapy? Ann Surg Oncol. 2026;33(2):1381\u201390.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"1795_CR28","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/jnci\/djn085","volume":"100","author":"G von Minckwitz","year":"2008","unstructured":"von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008;100(8):542\u201351.","journal-title":"J Natl Cancer Inst"},{"issue":"10437","key":"1795_CR29","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","volume":"403","author":"JM Perez-Garcia","year":"2024","unstructured":"Perez-Garcia JM, Cortes J, Ruiz-Borrego M, Colleoni M, Stradella A, Bermejo B, et al. 3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet. 2024;403(10437):1649\u201359.","journal-title":"Lancet"},{"issue":"1","key":"1795_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10120-025-01683-x","volume":"29","author":"I Yasufuku","year":"2026","unstructured":"Yasufuku I, Kinoshita T, Bando E, Kurokawa Y, Fujisaki M, Ojima H, et al. Safety, survival outcomes, and prognostic factors in conversion surgery for advanced gastric cancer: a sub-analysis of Japanese patients in the CONVO-GC-1 study. Gastric Cancer. 2026;29(1):177\u201390.","journal-title":"Gastric Cancer"},{"issue":"30","key":"1795_CR31","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.18632\/oncotarget.27658","volume":"11","author":"O Takashi","year":"2020","unstructured":"Takashi O, Takaki Y, Yohei M, Satoshi M, Michio Y. Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial. Oncotarget. 2020;11(30):2906\u201318.","journal-title":"Oncotarget"},{"key":"1795_CR32","doi-asserted-by":"publisher","first-page":"1528529","DOI":"10.3389\/fonc.2025.1528529","volume":"15","author":"Z Bao","year":"2025","unstructured":"Bao Z, Jia N, Zhang Z, Hou C, Yao B, Li Y. Prospects for the application of pathological response rate in neoadjuvant therapy for gastric cancer. Front Oncol. 2025;15:1528529.","journal-title":"Front Oncol"},{"key":"1795_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2024.06.051","author":"X Yu","year":"2024","unstructured":"Yu X, Lei W, Zhu L, Qi F, Liu Y, Feng Q. Robotic versus laparoscopic distal gastrectomy for gastric cancer: a systematic review and meta-analysis. Asian J Surg. 2024. https:\/\/doi.org\/10.1016\/j.asjsur.2024.06.051.","journal-title":"Asian J Surg"},{"issue":"1","key":"1795_CR34","doi-asserted-by":"publisher","first-page":"4668","DOI":"10.1038\/s41467-024-49013-6","volume":"15","author":"J Lu","year":"2024","unstructured":"Lu J, Xu BB, Zheng HL, Li P, Xie JW, Wang JB, et al. Robotic versus laparoscopic distal gastrectomy for resectable gastric cancer: a randomized phase 2 trial. Nat Commun. 2024;15(1):4668.","journal-title":"Nat Commun"},{"issue":"3","key":"1795_CR35","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s10120-015-0522-z","volume":"19","author":"A Guner","year":"2016","unstructured":"Guner A, Son T, Cho I, Kwon IG, An JY, Kim HI, et al. Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation. Gastric Cancer. 2016;19(3):951\u201360.","journal-title":"Gastric Cancer"},{"issue":"49","key":"1795_CR36","doi-asserted-by":"publisher","first-page":"e13525","DOI":"10.1097\/MD.0000000000013525","volume":"97","author":"K Tang","year":"2018","unstructured":"Tang K, Liu Y, Dong L, Zhang B, Wang L, Chen J, et al. Influence of thermal ablation of hepatic metastases from gastric adenocarcinoma on long-term survival: systematic review and pooled analysis. Medicine (Baltimore). 2018;97(49):e13525.","journal-title":"Medicine (Baltimore)"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01795-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-026-01795-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01795-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:04:44Z","timestamp":1793754284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-026-01795-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":36,"alternative-id":["1795"],"URL":"https:\/\/doi.org\/10.1007\/s10120-026-01795-y","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"13 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to update the copyright line","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Takeshi Kuwata has received consulting fees from GxD and honoraria from MSD and Astellas. Kohei Shitara has received research funding from Astellas Pharma, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharmaceutical, MSD, Amgen, Eisai, PRA Health Sciences, Syneos Health, AstraZeneca, PPD-SNBL K.K., TORAY, Incyte Biosciences Japan G.K., and Medpace Japan KK.; consulting fees from Bristol-Myers Squibb, Takeda Pharmaceuticals, Ono Pharmaceutical, Novartis, Daiichi Sankyo, Amgen, Boehringer Ingelheim, MSD, Astellas, Guardant Health Japan, Janssen, AstraZeneca, Zymeworks Biopharmaceuticals, ALX Oncology, Bayer, GlaxoSmithKline, HEALIOS, Moderna, Arcus Biosciences, AbbVie, CMIC, Elevation Oncology, Oncolys, Sanofi, Gilead Sciences, Leap Therapeutics, Phanes Therapeutics, Scandion Oncology, and Revolution Medicines; and honoraria from Bristol-Myers Squibb, Ono Pharmaceutical, Janssen, Eli Lilly, Astellas, and AstraZeneca. Takumi Habu, Takahiro Kinoshita, Daiki Terajima, Izuma Nakayama, Masahiro Yura, Mitsumasa Yoshida, Naoya Sakamoto declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Comprehensive informed consent regarding the retrospective study was obtained from all patients prior to treatment.","order":2,"name":"Ethics","label":"Human or animal rights","group":{"name":"EthicsHeading","label":"Declarations"}}]}}